CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
-
Strangled by jihadist blockade, Malians flee their desert town
-
US Supreme Court declines to hear case challenging same-sex marriage
-
'Fired-up' Fritz sees off Musetti in ATP Finals
-
Injured Courtois set to miss Belgium World Cup qualifiers
-
Bulatov, pillar of Russian contemporary art scene, dies at 92
-
Fritz sees off Musetti in ATP Finals
-
US strikes on alleged drug boats kill six more people
-
Sarkozy released from jail 'nightmare' pending appeal trial
-
COP30 has a mascot: the fiery-haired guardian of Brazil's forest
-
The Sudanese who told the world what happened in El-Fasher
-
Three things we learned from the Sao Paulo Grand Prix
-
ASC acquire majority share in Atletico Madrid
-
Ferrari boss tells Hamilton, Leclerc to drive, not talk
-
Bank of England seeks to 'build trust' in stablecoins
-
China suspends 'special port fees' on US vessels for one year
-
French court frees ex-president Sarkozy from jail pending appeal
-
No link between paracetamol and autism, major review finds
-
Typhoon Fung-wong floods Philippine towns, leaves 5 dead in its wake
-
France's Sarkozy says prison a 'nightmare' as prosecutors seek his release
-
Guinness maker Diageo picks new CEO after US tariffs cloud
-
China suspends 'special port fees' on US vessels
-
US senators take major step toward ending record shutdown
-
Typhoon Fung-wong leaves flooded Philippine towns in its wake
-
From Club Med to Beverly Hills: Assinie, the Ivorian Riviera
-
The 'ordinary' Arnie? Glen Powell reboots 'The Running Man'
-
Typhoon exposes centuries-old shipwreck off Vietnam port
-
French court to decide if ex-president Sarkozy can leave jail
-
China lifts sanctions on US units of South Korea ship giant Hanwha
-
Japan death row inmate's sister still fighting, even after release
-
Taylor sparks Colts to Berlin win as Pats streak hits seven
-
Dreyer, Pellegrino lift San Diego to 4-0 MLS Cup playoff win over Portland
-
Indonesia names late dictator Suharto a national hero
-
Fourth New Zealand-West Indies T20 washed out
-
Tanzania Maasai fear VW 'greenwashing' carbon credit scheme
-
Chinese businesswoman faces jail after huge UK crypto seizure
-
Markets boosted by hopes for deal to end US shutdown
-
Amazon poised to host toughest climate talks in years
-
Ex-jihadist Syrian president due at White House for landmark talks
-
Saudi belly dancers break taboos behind closed doors
-
The AI revolution has a power problem
-
Big lips and botox: In Trump's world, fashion and makeup get political
-
NBA champion Thunder rally to down Grizzlies
-
US senators reach deal that could end record shutdown
-
Weakening Typhoon Fung-wong exits Philippines after displacing 1.4 million
-
Lenny Wilkens, Basketball Hall of Famer as player and coach, dies
-
LiberNovo Launches Black Friday Savings: Redefine Your Workspace for Health
-
Montlick Partners with 11Alive for Veterans Day Telethon Benefiting Top Dogg K9 Foundation
-
Envirotech Secures 80-Drone Deposits, Rapidly Expanding Drone Business
-
Nexscient(R) and Tekcapital Form Strategic Alliance to Accelerate AI-Driven Technology Acquisitions
-
BeenVerified People Search Tool Reunites a Family in Crisis
NYSE - LSE
| RYCEF | 0.13% | 14.82 | $ | |
| NGG | -0.48% | 77.375 | $ | |
| RBGPF | 0% | 76 | $ | |
| BTI | 0.05% | 54.615 | $ | |
| BP | -0.17% | 36.519 | $ | |
| RIO | 0.65% | 69.782 | $ | |
| RELX | -0.96% | 41.87 | $ | |
| CMSC | -0.04% | 23.84 | $ | |
| VOD | -0.09% | 11.57 | $ | |
| SCS | -0.29% | 15.715 | $ | |
| CMSD | 0.41% | 24.2 | $ | |
| BCC | -1.09% | 69.875 | $ | |
| GSK | -0.05% | 46.605 | $ | |
| AZN | 1.5% | 85.87 | $ | |
| JRI | -0.29% | 13.7 | $ | |
| BCE | -1.18% | 22.92 | $ |
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that three abstracts have been selected for poster presentation at the 2025 SNO Annual Meeting being held November 19-23, 2025 in Honolulu, HI.
Details of the poster presentations are as follows:
Title: Activity of Berubicin against Pediatric Diffuse Midline Glioma (DMG) cells: Preliminary data and future possibilities
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: EXTH-133
Date and Time: Friday, November 21, 2025 at 11:45 am - 1:05 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
Title: TPI 287, which in combination with Bevacizumab (BEV) has shown activity in patients with glioblastoma (GBM) after prior therapy, will be evaluated in a Phase 2 trial as well as in other CNS diseases
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: CTNI-70
Date and Time: Saturday, November 22, 2025 at 11:45 am - 1:05 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
Title: Primary results of the randomized clinical trial of Berubicin vs Lomustine in patients with glioblastoma after failure of primary therapy: Data analysis and future possibilities
Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals
Abstract Code: CTNI-74
Date and Time: Saturday, November 22, 2025 at 11:30 am - 12:45 pm HST
Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III
For more information about the event, please visit the meeting website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
J.Williams--AMWN